TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study

详细信息    查看全文

• 作者：David G Cox (1) (2)
  Kathryn Penney (1)
  Qun Guo (2)
  Susan E Hankinson (2)
  David J Hunter (1) (2)
  
• 刊名：BMC Cancer
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：7
• 期：1
• 全文大小：528KB
• 参考文献：1. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. / Nature 1994, 371: 257鈥?61. CrossRef
  2. Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. / Genes Dev 1995, 9: 1831鈥?845. CrossRef
  3. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. / Proc Natl Acad Sci U S A 1995, 92: 5545鈥?549. CrossRef
  4. Coffey RJ Jr., Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL: Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. / Mol Cell Biol 1988, 8: 3088鈥?093.
  5. Ewen ME, Oliver CJ, Sluss HK, Miller SJ, Peeper DS: p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. / Genes Dev 1995, 9: 204鈥?17. CrossRef
  6. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. / Cell 1993, 74: 1009鈥?020. CrossRef
  7. Iavarone A, Massague J: Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. / Nature 1997, 387: 417鈥?22. CrossRef
  8. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. / Mol Cell Biol 1999, 19: 916鈥?22.
  9. Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP, Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. / Proc Natl Acad Sci U S A 1987, 84: 837鈥?41. CrossRef
  10. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. / Cancer Res 1987, 47: 707鈥?12.
  11. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, / et al.: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. / Proc Natl Acad Sci U S A 1986, 83: 4167鈥?171. CrossRef
  12. Madri JA, Pratt BM, Tucker AM: Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. / J Cell Biol 1988, 106: 1375鈥?384. CrossRef
  13. Yang EY, Moses HL: Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. / J Cell Biol 1990, 111: 731鈥?41. CrossRef
  14. Gajdusek CM, Luo Z, Mayberg MR: Basic fibroblast growth factor and transforming growth factor beta-1: synergistic mediators of angiogenesis in vitro. / J Cell Physiol 1993, 157: 133鈥?44. CrossRef
  15. Choi ME, Ballermann BJ: Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. / J Biol Chem 1995, 270: 21144鈥?1150. CrossRef
  16. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. / J Biol Chem 1994, 269: 6271鈥?274.
  17. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. / Cancer 1999, 86: 1455鈥?462. CrossRef
  18. Fortunel NO, Hatzfeld A, Hatzfeld JA: Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. / Blood 2000, 96: 2022鈥?036.
  19. Ashcroft GS: Bidirectional regulation of macrophage function by TGF-beta. / Microbes Infect 1999, 1: 1275鈥?282. CrossRef
  20. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. / Annu Rev Immunol 1998, 16: 137鈥?61. CrossRef
  21. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD: Genetic control of the circulating concentration of transforming growth factor type beta1. / Hum Mol Genet 1999, 8: 93鈥?7. CrossRef
  22. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. / Cancer Res 2003, 63: 2610鈥?615.
  23. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS: Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. / Jama 2001, 285: 2859鈥?863. CrossRef
  24. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE: T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. / Cancer Epidemiol Biomarkers Prev 2004, 13: 412鈥?15.
  25. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Bahadori B, Samonigg H: The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. / Cancer Lett 2003, 201: 181鈥?84. CrossRef
  26. Breast Cancer Association C: Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. / J Natl Cancer Inst 2006, 98: 1382鈥?396. CrossRef
  27. Walker RA: Transforming growth factor beta and its receptors: their role in breast cancer. / Histopathology 2000, 36: 178鈥?80. CrossRef
  28. Luo K, Lodish HF: Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. / Embo J 1996, 15: 4485鈥?496.
  29. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massague J, Offit K: TbetaR-I(6A) is a candidate tumor susceptibility allele. / Cancer Res 1999, 59: 5678鈥?682.
  30. Chen T, de Vries EG, Hollema H, Yegen HA, Vellucci VF, Strickler HD, Hildesheim A, Reiss M: Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. / Int J Cancer 1999, 82: 43鈥?1. CrossRef
  31. Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T: TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. / J Clin Oncol 2004, 22: 756鈥?58. CrossRef
  32. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B: Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. / Cancer Res 2005, 65: 3454鈥?461.
  33. Glynn RJ, Rosner B: Methods to evaluate risks for composite end points and their individual components. / J Clin Epidemiol 2004, 57: 113鈥?22. CrossRef
  34. Gauderman WJ: Sample size requirements for matched case-control studies of gene-environment interaction. / Stat Med 2002, 21: 35鈥?0. CrossRef
  35. Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W, Forsti A: Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. / Int J Cancer 2004, 112: 94鈥?9. CrossRef
  36. Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE: Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. / Cancer Epidemiol Biomarkers Prev 2006, 15: 1236鈥?237. CrossRef
  37. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B: TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. / J Clin Oncol 2003, 21: 3236鈥?243. CrossRef
  38. Baxter SW, Choong DY, Eccles DM, Campbell IG: Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. / Cancer Epidemiol Biomarkers Prev 2002, 11: 211鈥?14.
  39. Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE, Pemberton JO, Deddens JA, Graff JR, Carter JH: Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer. / Clin Cancer Res 2006, 12: 392鈥?97. CrossRef
  40. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, Dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schurmann P, Bogdanova N, Dork T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G, Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedren S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF: A common coding variant in CASP8 is associated with breast cancer risk. / Nat Genet 2007, 39: 352鈥?58. CrossRef
  41. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr., Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. / Nat Genet 2007.
  42. Barcellos-Hoff MH: Transforming growth factor beta's role in mammary gland development and carcinogenesis. / Breast Cancer Res 2003, 5: 33. CrossRef
  43. Anderson E, Clarke RB: Steroid receptors and cell cycle in normal mammary epithelium. / J Mammary Gland Biol Neoplasia 2004, 9: 3鈥?3. CrossRef
  44. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/175/prepub
  
• 作者单位：David G Cox (1) (2)
  Kathryn Penney (1)
  Qun Guo (2)
  Susan E Hankinson (2)
  David J Hunter (1) (2)
  
  1. Program in Molecular and Genetic Epidemiology, Epidemiology Department, Harvard School of Public Health, USA
  2. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA
  
• ISSN：1471-2407

文摘

Background Transforming growth factor beta 1 (TGFB1) forms a signaling complex with transforming growth factor beta receptors 1 and 2 and has been described as both a tumor suppressor and tumor promoter. Single nucleotide polymorphisms in TGFB1 and a microsatellite in TGFBR1 have been investigated for association with risk of breast cancer, with conflicting results. Methods We examined polymorphisms in the promoter region of the TGFB1 gene as well as the TGFBR1*6A microsatellite in the Nurses' Health Study cohort. Results No overall associations between the L10P polymorphism of TGFB1 or the TGFBR1 microsatellite were detected. However, we observed an inverse association between the -509 C/T polymorphism of TGFB1 (p-trend = 0.04), which was stronger and more significant among women with estrogen receptor positive breast cancer. Conclusion Polymorphisms in the promoter region of TGFB1 are not likely to be associated with large increases in breast cancer risk overall among Caucasian women.